Non-Invasive Cancer Monitoring
Trovagene's industry-leading cancer mutation testing is the first to be totally and truly non-invasive. It detects cell-free tumor DNA in the urine rather than in the blood or tissue of cancer patients. This new technology may provide new insights into tumor mutations, therapeutic response and overall tumor burden.
Find out more »
State-of-the-Art Mutation Detection
Trovagene uses the latest and most advanced DNA sequencing technology to provide molecular diagnostic services through its CLIA-certified, CAP-accredited laboratory in San Diego. This modern facility is backed by a strong foundation in basic research into novel diagnostics and markers and has a growing list of available tests and panels.
Truly Non-Invasive Diagnostic Technology
Trovagene's cell-free nucleic acid technology is enabling the development of non-invasive ways to detect, quantify and monitor genetic markers and gene mutations in urine.
What are Cell-Free Nucleic Acids?
Scientists used to think that DNA and RNA were only found within cells. With the advent of more sensitive detection equipment these nucleic acids were found in blood plasma. Trovagene scientists were the first to make the simple yet remarkable discovery that these cell-free nucleic acids filter through the kidney and appear in urine.